JAMA recently published a concise explainer article on peanut allergy, showing how introducing peanuts early in infancy can substantially reduce risk, alongside a summary of diagnosis and treatment.
Peanut allergy is an immune reaction to peanut proteins that can trigger skin, gastrointestinal, respiratory, and cardiovascular symptoms, and in rare cases, life-threatening anaphylaxis. It affects about 2% of people in the US, usually developing in early childhood, though 10-30% of children outgrow it.
Diagnosis is based on a history of allergic reactions within 1-2 hours of peanut exposure and may be confirmed with a positive skin prick test or a blood test that detects antibodies to peanuts. Severe reactions are treated immediately with epinephrine, which remains the first-line therapy.
In the past few years, the U.S. Food and Drug Administration has approved additional therapies for managing peanut allergy. Oral immunotherapy gradually desensitizes most patients to small amounts of peanut protein, though it requires ongoing daily ingestion and careful monitoring. The biologic medication omalizumab, approved for patients aged one year and older, helps roughly two-thirds of patients achieve desensitization with a manageable dosing schedule.
Prevention is where the most encouraging progress has been made. A 2017 guideline from the National Institute of Allergy and Infectious Diseases (NIAID) recommends introducing peanuts into the diets of infants—particularly those with eczema or egg allergy—from around 4 months of age. Since the guideline’s publication, research has shown a significant decrease in peanut allergy diagnoses among infants, highlighting the potential of early introduction to substantially reduce risk.
This JAMA article underscores that, while peanut allergy can be serious, early dietary strategies combined with modern therapies are shifting the outlook in a positive direction.